December 2024
https://ekstrabladet.dk/penge/dansk-biotekkomet-lander-kaempe-aftale-paa-50-mio.-dollars/10482761
har landet en aftale, der kan sikre selskabet mere end 50 millioner dollars
https://www.euroinvestor.dk/nyheder/markedsanalytiker-er-gubra-den-naeste-vaegttabsblockbuster
R&D-pipeline med fokus på peptide-baserede lægemidler, herunder vægttabsmidler
Danish biotech company Gubra has partnered with Amylyx Pharmaceuticals to develop a novel long-acting GLP-1 receptor antagonist, according to a press release.
"We are pleased to partner with Amylyx to advance research in GLP-1 receptor antagonism. This collaboration and development agreement is an example of leading pharmaceutical companies partnering with us for our machine learning-based peptide drug discovery platform. This is further proof that our streaMLine platform can be used to develop peptide drug candidates for a very wide range of diseases", says CEO Henrik Blou.
=============== efterår 2024 ===================
https://ekstrabladet.dk/penge/glem-wegovy-her-er-fremtidens-fedmeraketter/10460263
"Ifølge professoren er Novo længst med den nye udvikling - stærkt forfulgt at danske biotekselskaber som Zealand Pharma og Gubra"
https://borsen.dk/overblik/virksomhed/gubra
https://ugebrev.dk/virksomhed/gubra/
https://www.berlingske.dk/emne/gubra